Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study
Eiji Oki(Kyushu University), Yoshihiko Maehara(Kyushu University), Hiroshi Saeki(Kyushu University), Yoshihiro Kakeji(Kobe University), Masanori Kon(Kansai Medical University), Naohiro Tomita(Toyonaka Municipal Hospital), Jun Higashijima(Tokushima University), Yasunori Emi(Saiseikai Fukuoka General Hospital), Yasuhiro Miyake(High Energy Accelerator Research Organization), Hideyuki Ishida(Tokyo Medical and Dental University), Takeshi Kato(Osaka National Hospital), Hideo Baba(Kaketsuken (Japan)), Hiroshi Kojima(Ibaraki Prefectural Central Hospital), Yoshihisa Sakaguchi(National Kyushu Medical Center), Kenichi Takahashi(Tohoku Rosai Hospital), Toru Kono(Asahikawa Medical College Hospital), Takeharu Yamanaka(National Cancer Center Hospital East), Yutaka Ogata(Kurume University Medical Center), Ken Shirabe(Gunma University)
Cited by 96
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2011|713
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600